Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ATG7 | O95352 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.36 |
| ▸ | UBA7 | P41226 | 1/20 | 0.36 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.36 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630925 | 0.90 | BCHE (0.41) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL18630442 | 0.88 | BCHE (0.40) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL18630443 | 0.85 | BCHE (0.38) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL12566441 | 0.83 | BCHE (0.43) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL1796915 | 0.81 | CA1 (0.54) | ATG7UBA6UBA7NAE1UBA3 | |
| SCHEMBL12652428 | 0.79 | BCHE (0.43) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL13773372 | 0.76 | BCHE (0.54) | BCHEALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12566802 | 0.76 | BCHE (0.44) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL12567150 | 0.76 | BCHE (0.47) | BCHEATG7UBA6UBA7NAE1 | |
| SCHEMBL12566427 | 0.75 | DNPH1 (0.47) | BCHEATG7ABL1UBA6UBA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | BCHE 151/4885ATG7 2417/4885ABL1 2724/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | BCHE 151/4885ATG7 2417/4885ABL1 2724/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | BCHE 24/4885ATG7 1114/4885ABL1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.